BUND FINANCE

BUND FINANCE › Stocks › BSX

Boston Scientific Corporation (BSX)

NYSE · Stock price, chart and technical analysis

US$43.64+0.6100 (+1.42%)

Data from Financial Modeling Prep · Nov 18, 2026, 4:00 PM New York time · may be delayed

Open the live chartSee Technicals⏱ Analyze entryQuarterly earnings📅 See in calendar💬 Explain this move⇄ ComparePractice in the Simulator

Key stats

Previous closeUS$43.03
OpenUS$42.50
Day rangeUS$42.50 – US$44.32
52-week rangeUS$39.57 – US$101.91
Market capUS$63.25B
Volume13.21M
50-day averageUS$43.89
200-day averageUS$53.65
Beta0.59

Quick technical read

This describes price action; it is not a recommendation. The app also calculates RSI, MACD, the entry setup and 30+ indicators. How we calculate it

Fundamentals Annual

Fiscal year20212022202320242025
RevenueUS$11.9BUS$12.7BUS$14.2BUS$16.7BUS$20.1B
Net incomeUS$1.0BUS$698.0MUS$1.6BUS$1.9BUS$2.9B
EPS (diluted)0.690.451.071.251.94
Gross margin68.8%60.8%62.0%61.3%69.0%
Operating margin10.1%14.4%15.3%15.7%19.8%
Net margin8.8%5.5%11.2%11.1%14.4%
Free cash flowUS$1.3BUS$938.0MUS$1.8BUS$2.6BUS$3.7B
Total debtUS$9.5BUS$9.3BUS$9.5BUS$11.1BUS$12.4B
CashUS$1.9BUS$928.0MUS$865.0MUS$414.0MUS$2.0B

Compound annual growth: revenue 14.0% · net income 29.1% (4 years).

Valuation: today, its history and its sector

Today5-year averageSector median (Healthcare)
P/E18.5x67.5x27.1x
EV / EBITDA13.8x29.4x16.5x
Operating margin21.1%—3.6%
Net margin16.6%—-0.0%
Debt / equity0.76—0.58

Source: annual financial statements from Financial Modeling Prep. “Today” uses the current price and the last 4 quarters. The sector median uses U.S. companies above US$300M market cap. A multiple above or below its history or sector is not a recommendation.

About Boston Scientific Corporation

SectorHealthcare
IndustryMedical - Devices
CountryUS
CEOMichael F. Mahoney
Employees59,000
IPO date1992-05-19

Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns. This extends to advanced implantable devices for managing cardiac rhythm disorders, such as cardioverter-defibrillators, …

www.bostonscientific.com

Other stocks on BUND FINANCE

Not financial advice. BUND FINANCE publishes general information for educational purposes. Investing involves risk, including loss of capital. Legal notice